Last reviewed · How we verify

NCT06127550

taVNS for Letter Learning in Dyslexia

Suspended NA Last updated 11 December 2025
What this trial tests

NA trial testing active taVNS in Dyslexia in 100 participants. Suspended.

Timeline
1 August 2026
Primary endpoint
1 August 2028
1 September 2029

Quick facts

Lead sponsorUniversity of Florida
PhaseNA
StatusSuspended
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposebasic science
Enrollment100
Start date1 August 2026
Primary completion1 August 2028
Estimated completion1 September 2029
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Florida

Who can join

Adults 10 to 12, any sex, with Dyslexia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a pilot study to establish feasibility of transcutaneous auricular vagus nerve stimulation (taVNS) for improving letter-learning in adolescents with dyslexia. The main goals of the study are to 1) evaluate whether children in this age range will tolerate low level stimulation over the course of multiple sessions, 2) determine whether low level taVNS improves novel letter learning in dyslexia, and 3) evaluate the effect of low level taVNS on the brain's response to letters. Participants will complete fMRI before training, immediately after training, and a few weeks after training ends. Training will consist of six 30-minute lessons during which participants will learn novel letter-sound relationships while receiving either active or sham taVNS. Researchers will compare stimulation conditions to determine effect of this device on learning and neural plasticity.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of active taVNS

Trials testing the same drug.

Other recruiting trials for Dyslexia

Currently open trials in the same condition.

Other University of Florida trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06127550.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing